US-based global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX) announced on Monday that it has named Michael Feld as its new executive vice president and president of the Life Sciences segment for BD, effective 20 August 2024.

Feld is to serve as a member of the executive leadership team and will succeed Dave Hickey, who retired from BD last month after 10 years with the company.

Feld has served at Veralto, where he was most recently president of Hach. He has served in various senior roles at Danaher, which includes senior vice president and general manager of Cepheid Europe, and worked as president of various other Danaher businesses including Mammotome, XOS and Dover Motion.

Tom Polen, BD chairman, CEO and president, said, 'Mike's expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences segment. As we build momentum behind our BD Excellence operating system, Mike's continuous improvement mindset will be an asset to BD as our Life Sciences team continues to drive efficiencies and meaningfully expand value for our customers, their patients and the global healthcare ecosystem.'